The review found no eligible studies for this question.
One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) may leads to lower faliure to induce clinical response at 8 weeks compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in failure to induce remission at 6 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 4 weeks compared with placebo (high certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce remission at 10 weeks compared with placebo (high certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce clinical response at 10 weeks compared with placebo (high certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in withdrawal due to adverse event up to week 12 compared with placebo (moderate certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 2 weeks compared with placebo (moderate certainty).